Golden has been acquired by ComplyAdvantage.Read about it here ⟶

List of Exelixis Ltd patents

List of Exelixis Ltd patents

List of Advanced Orthopaedic Solutions patents

List of Varian Medical Systems patents

List of Seaspine patents

List of NGOs in Camarillo, California

List of companies in Aldrich Capital Partners's investment portfolio

Patents where

Current Assignee

Name

is

‌

Exelixis Ltd

	Name	Description	Patent Applicant	Current Assignee	Inventor	Patent Jurisdiction	Patent Number	Date of Patent
	‌ US Patent 11124482 C-met modulators and methods of use	Patent 11124482 was granted and assigned to Exelixis Ltd on September, 2021 by the United States Patent and Trademark Office.	‌ Exelixis Ltd	‌ Exelixis Ltd		United States Patent and Trademark Office	11124482	September 21, 2021
	‌ US Patent 11098015 Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer	Patent 11098015 was granted and assigned to Exelixis Ltd on August, 2021 by the United States Patent and Trademark Office.	‌ Exelixis Ltd	‌ Exelixis Ltd		United States Patent and Trademark Office	11098015	August 24, 2021
	‌ US Patent 11091439 Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer	Patent 11091439 was granted and assigned to Exelixis Ltd on August, 2021 by the United States Patent and Trademark Office.	‌ Exelixis Ltd	‌ Exelixis Ltd		United States Patent and Trademark Office	11091439	August 17, 2021
	‌ US Patent 11091440 Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer	Patent 11091440 was granted and assigned to Exelixis Ltd on August, 2021 by the United States Patent and Trademark Office.	‌ Exelixis Ltd	‌ Exelixis Ltd		United States Patent and Trademark Office	11091440	August 17, 2021
	‌ US Patent 10034873 C-met modulator pharmaceutical compositions	Patent 10034873 was granted and assigned to Exelixis Ltd on July, 2018 by the United States Patent and Trademark Office.	Exelixis	‌ Exelixis Ltd		United States Patent and Trademark Office	10034873	July 31, 2018
	‌ US Patent 10039757 C-Met modulator pharmaceutical compositions	Patent 10039757 was granted and assigned to Exelixis Ltd on August, 2018 by the United States Patent and Trademark Office.	Exelixis	‌ Exelixis Ltd		United States Patent and Trademark Office	10039757	August 7, 2018
	‌ US Patent 10159666 Dosing of cabozantinib formulations	Patent 10159666 was granted and assigned to Exelixis Ltd on December, 2018 by the United States Patent and Trademark Office.	Exelixis	‌ Exelixis Ltd		United States Patent and Trademark Office	10159666	December 25, 2018
	‌ US Patent 10166225 Method for treating osteoporosis	Patent 10166225 was granted and assigned to Exelixis Ltd on January, 2019 by the United States Patent and Trademark Office.	Exelixis	‌ Exelixis Ltd		United States Patent and Trademark Office	10166225	January 1, 2019
	‌ US Patent 10123999 Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds	Patent 10123999 was granted and assigned to Exelixis Ltd on November, 2018 by the United States Patent and Trademark Office.	‌ Exelixis Ltd	‌ Exelixis Ltd		United States Patent and Trademark Office	10123999	November 13, 2018
	‌ US Patent 10273211 Metabolites of N-{4-([6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide	Patent 10273211 was granted and assigned to Exelixis Ltd on April, 2019 by the United States Patent and Trademark Office.	Exelixis	‌ Exelixis Ltd		United States Patent and Trademark Office	10273211	April 30, 2019
	‌ US Patent 11141413 Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate	Patent 11141413 was granted and assigned to Exelixis Ltd on October, 2021 by the United States Patent and Trademark Office.	‌ Exelixis Ltd	‌ Exelixis Ltd		United States Patent and Trademark Office	11141413	October 12, 2021
	‌ US Patent 11124481 Method of preparing fluorine-18 labeled Cabozantinib and its analogs	Patent 11124481 was granted and assigned to Exelixis Ltd on September, 2021 by the United States Patent and Trademark Office.	‌ Exelixis Ltd	‌ Exelixis Ltd		United States Patent and Trademark Office	11124481	September 21, 2021
	‌ US Patent 10328069 Phosphatidylinositol 3-kinase inhibitors for the treatment of lymphoproliferative malignancies	Patent 10328069 was granted and assigned to Exelixis Ltd on June, 2019 by the United States Patent and Trademark Office.		‌ Exelixis Ltd		United States Patent and Trademark Office	10328069	June 25, 2019
	‌ US Patent 11123338 C-met modulator pharmaceutical compositions	Patent 11123338 was granted and assigned to Exelixis Ltd on September, 2021 by the United States Patent and Trademark Office.	‌ Exelixis Ltd	‌ Exelixis Ltd		United States Patent and Trademark Office	11123338	September 21, 2021
	‌ US Patent 11198731 Combinations of cabozantinib and atezolizumab to treat cancer	Patent 11198731 was granted and assigned to Exelixis Ltd on December, 2021 by the United States Patent and Trademark Office.	‌ Exelixis Ltd	‌ Exelixis Ltd		United States Patent and Trademark Office	11198731	December 14, 2021
	‌ US Patent 10053470 Inhibitors of PI3K-delta and methods of their use and manufacture	Patent 10053470 was granted and assigned to Exelixis Ltd on August, 2018 by the United States Patent and Trademark Office.	Exelixis	‌ Exelixis Ltd		United States Patent and Trademark Office	10053470	August 21, 2018
	‌ US Patent 8362002 Azetidines as MEK inhibitors for the treatment of proliferative diseases	Patent 8362002 was granted and assigned to Exelixis Ltd on January, 2013 by the United States Patent and Trademark Office.		‌ Exelixis Ltd		United States Patent and Trademark Office	8362002	January 29, 2013
	‌ US Patent 11116759 Method of treating cancer	Patent 11116759 was granted and assigned to Exelixis Ltd on September, 2021 by the United States Patent and Trademark Office.	‌ Exelixis Ltd	‌ Exelixis Ltd		United States Patent and Trademark Office	11116759	September 14, 2021

18 results

0 selected

18 results

0 selected